<DOC>
	<DOCNO>NCT01949818</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Yangzhengxiaoji Capsule Combination Chemotherapy III/IV Diffuse Large B Cell Lymphoma .</brief_summary>
	<brief_title>Treatment Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Age range 1470 year old ; ECOG performance status 02 ; Estimated survival time &gt; 3 month Histological confirm Diffuse large B cell lymphoma ( III/IV ) None chemotherapy radiotherapy previously use None chemotherapy contraindication : hemoglobin ≥ 90 g/dl , neutrophil ≥ 1.5×109/L , platelet ≥ 100×109/L , ALT AST ≤ 2×ULN , serum bilirubin ≤ 1.5×ULN , serum creatine ≤ 1.5×upper limitation normal ( ULN ) , Serum Albumin ≥ 30g/L At least one measurable lesion None serious disease , cardiopulmonary function normal Pregnancy test woman reproductive age must negative Patients could follow None relative treatment include traditional Chinese medicine , immunotherapy , biotherapy except antibone metastasis therapy symptomatic treatment . Disagreement blood sample collection Patients allergic drug regimen metabolic disorder Pregnant lactate woman Serious medical illness likely interfere participation Serious infection Primitive secondary tumor central nervous system Chemotherapy radiotherapy contraindication The evidence CNS metastasis History peripheral nervous disorder dysphrenia patient participate clinical trial patient take antitumor drug patient estimate unsuitable investigation</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>